AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Centessa Pharmaceuticals plc Director's Dealing 2021

Oct 9, 2021

31309_dirs_2021-10-08_80729220-a1cf-4ef1-912c-9e4301399a4d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Centessa Pharmaceuticals plc (CNTA)
CIK: 0001847903
Period of Report: 2021-10-01

Reporting Person: GRAINGER DAVID J (Chief Innovation Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	813756	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Share Option (right to buy)	$9.42	2031-05-07	Ordinary Shares (150000)		Direct

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: 25% of the shares subject to such option shall vest and become exercisable on May 7, 2022 and the remaining 75% of the shares subject to such option shall vest and become exercisable in 36 monthly installments on the first day of each month thereafter.